Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Mayo Clinic Florida

Neither a doctor nor a teaching hospital

Research payments

$4,365,942

234 payments

Through program year 2025, Mayo Clinic Florida is reported as receiving $4,365,942 in research payments, across 234 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $72,282 9
2024 Research $1,273,059 109
2023 Research $451,385 39
2022 Research $524,138 20
2021 Research $1,272,354 28
2020 Research $688,464 20
2019 Research $84,261 9

Breakdown

Who paid Research payments · program years 2019–2025
  1. Amgen Inc. $1,856,870 29 payments
  2. Pfizer Inc. $869,722 41 payments
  3. AbbVie, Inc. $553,030 29 payments
  4. Daiichi Sankyo Company LTD $375,000 3 payments
  5. Merck Sharp & Dohme Corporation $200,946 21 payments
  6. TG Therapeutics, Inc. $197,247 25 payments
  7. Insmed, Inc. $155,268 73 payments
  8. Pharmacyclics LLC, An AbbVie Company $114,961 2 payments
  9. E.R. Squibb & Sons, L.L.C. $41,413 6 payments
  10. Alcon Research LLC $1,250 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. AMG 701 P1/2 Non-Randomized Open-Label Expansion MM $1,421,089 4 payments
  2. A Randomized Doubleblind Phase 3 Study of Tucatinib Or Placebo in Combination With Trastuzumab and Pertuzumab As Maintenance Therapy for Metastatic Her2 Breast Cancer Her2climb05 $578,892 22 payments
  3. AMG 701 Ph1/2 Non-Randomized Open-Label Expansion MM $281,739 2 payments
  4. Openlabel Phase 1 Study of Sgnb7h4v for Solid Tumors $263,572 13 payments
  5. A Safety and Efficacy Study of Intravenous (IV) Elezanumab Assessing Change in Neurologic Function in Adult Participants With Acute Ischemic Stroke $260,342 23 payments
  6. A Phase II Study of Ibrutinib as Prophylaxis For Chronic Graft-Versus-Host Disease (GVHD) in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation (all-HCT) $248,218 2 payments
  7. ULTRA-V: Phase 2/3 Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with Umbralisib and Venetoclax (U2-V) Compared to Ublituximab and Umbralisib (U2) in Subjects with Chronic Lymphocytic Leukemia (CLL) $181,703 21 payments
  8. Phase 2 study of Ibrutinib for prophylaxis against chronic graft-versus-host disease $114,961 2 payments
  9. A Phase 2b, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension $76,360 15 payments
  10. Adjuvant Therapy with Pembrolizumab versus Placebo in Resected High Risk Stage II Melanoma# A Randomized, Double-blind Phase III Study KEYNOTE 716 $73,668 5 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record